Quick Answer
AN2 Therapeutics, Inc. reported Stockholders Equity of $53.06 million for fiscal year 2025.
AN2 Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $53.06M | -35.2% |
| 2024 | $81.85M | -34.4% |
| 2023 | $124.70M | +30.8% |
| 2022 | $95.37M | +301.2% |
| 2021 | -$47.41M | -133.3% |
| 2020 | -$20.32M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $60.38M | -31.1% | -12.3% |
| June 30, 2025 | $68.84M | -30.0% | -6.1% |
| March 31, 2025 | $73.33M | -33.7% | -10.4% |
| December 31, 2024 | $81.85M | -34.4% | -6.6% |
| September 30, 2024 | $87.67M | -36.9% | -10.9% |
| June 30, 2024 | $98.35M | +12.1% | -11.1% |
| March 31, 2024 | $110.60M | +34.0% | -11.3% |
| December 31, 2023 | $124.70M | +30.8% | -10.3% |
- AN2 Therapeutics, Inc. showed a decrease of -35.2% in Stockholders Equity compared to the prior fiscal year.
- Over the 2020–2025 period, AN2 Therapeutics, Inc.’s stockholders equity has grown by 361.1% (from -$20.32 million to $53.06 million).
- The most recent figure is from AN2 Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: